Alector, Inc. (NASDAQ:ALEC - Free Report) - Analysts at HC Wainwright increased their FY2026 earnings per share estimates for Alector in a report issued on Wednesday, October 22nd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $0.16 per share for the year, up from their previous estimate of ($1.71). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Alector's current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for Alector's FY2027 earnings at $0.16 EPS, FY2028 earnings at ($1.40) EPS and FY2029 earnings at ($1.15) EPS.
Alector (NASDAQ:ALEC - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. The business had revenue of $7.87 million for the quarter, compared to analyst estimates of $2.76 million. Alector has set its FY 2025 guidance at EPS.
Other analysts have also issued reports about the stock. Cowen lowered shares of Alector to a "hold" rating in a research report on Wednesday. BTIG Research downgraded Alector from a "buy" rating to a "neutral" rating in a research report on Wednesday. Cantor Fitzgerald downgraded Alector from an "overweight" rating to a "neutral" rating in a research report on Wednesday. TD Cowen downgraded Alector from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Wall Street Zen downgraded Alector from a "hold" rating to a "sell" rating in a research report on Friday, September 26th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Alector currently has a consensus rating of "Reduce" and a consensus target price of $3.00.
Check Out Our Latest Report on ALEC
Alector Price Performance
Alector stock opened at $1.47 on Friday. The firm's 50-day simple moving average is $2.79 and its 200 day simple moving average is $1.88. The firm has a market capitalization of $148.78 million, a PE ratio of -1.27 and a beta of 0.99. Alector has a 52 week low of $0.87 and a 52 week high of $6.14. The company has a quick ratio of 3.78, a current ratio of 3.78 and a debt-to-equity ratio of 0.13.
Insider Activity
In other news, Director Paula Hammond sold 14,000 shares of the firm's stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total transaction of $33,040.00. Following the sale, the director owned 74,909 shares in the company, valued at $176,785.24. This trade represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.70% of the stock is owned by company insiders.
Institutional Investors Weigh In On Alector
Several hedge funds have recently made changes to their positions in ALEC. HBK Sorce Advisory LLC purchased a new stake in Alector in the 3rd quarter valued at about $34,000. Hamilton Lane Advisors LLC purchased a new stake in Alector in the 3rd quarter valued at about $43,000. FNY Investment Advisers LLC increased its position in Alector by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 20,000 shares of the company's stock worth $28,000 after purchasing an additional 10,000 shares during the last quarter. Prudential Financial Inc. purchased a new position in Alector during the second quarter worth approximately $30,000. Finally, CWM LLC raised its stake in Alector by 370.7% during the first quarter. CWM LLC now owns 33,643 shares of the company's stock worth $41,000 after purchasing an additional 26,495 shares during the period. Institutional investors and hedge funds own 85.83% of the company's stock.
Alector Company Profile
(
Get Free Report)
Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alector, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alector wasn't on the list.
While Alector currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
